Autologous Stem Cell Transplantation Versus Alternative Allogeneic Donor Transplants in Adult Acute Leukemias

The availability of alternative sources of stem cells including most recently T replete haploidentical marrow or peripheral blood, and the increasing use of reduced intensity conditioning renders feasible an allogeneic transplant to almost all patients with acute leukemia up to 70 years of age. Autologous stem cell transplantation for consolidation of complete remission, however, offers in some circumstances an alternative option. Although associated with a higher relapse rate, autologous transplant benefits from a lower non relapse mortality, the absence of graft versus host disease and a better quality of life for long term survivors.
Source: Seminars in Hematology - Category: Hematology Authors: Source Type: research